The Conversation (0)
BrainsWay Announces its Multicenter Smoking Cessation Study Has Reached Target Enrollment
May. 22, 2019 08:55AM PST
Medical Device InvestingBrainsWay (NASDAQ:BWAY) has announced it has reached its target recruitment for its multicenter study for the safety and efficacy of its deep transcranial stimulation system (Deep TMS) used for smoking cessation and patients with a chronic smoking addiction. As quoted in the press release: Yaacov Michlin, President and Chief Executive Officer of BrainsWay, said, “We …
BrainsWay (NASDAQ:BWAY) has announced it has reached its target recruitment for its multicenter study for the safety and efficacy of its deep transcranial stimulation system (Deep TMS) used for smoking cessation and patients with a chronic smoking addiction.
As quoted in the press release:
Yaacov Michlin, President and Chief Executive Officer of BrainsWay, said, “We believe there is a considerable unmet need for a safe and efficient solution for cigarette addiction. We look forward to receiving the results of the study, which, if successful, could lead to a novel, non-invasive, safe and effective approach for people willing to quit smoking.”
BrainsWay’s Deep TMS device is designed to effectively stimulate deep and broad areas of the brain. The BrainsWay H4-Coil used in this study is designed to non-invasively stimulate specific brain regions known to be associated with addiction, including the bilateral insula and prefrontal cortex, using brief magnetic fields at an amplitude similar to that used in magnetic resonance imaging (MRI) systems. The H4-coil is situated in a helmet, but is different than the Company’s already FDA-cleared coils : H1 for the treatment of depressive episodes in adult patients suffering from Major Depressive Disorder (MDD) who failed to achieve satisfactory improvement from previous anti-depressant medication treatment in the current episode and H7 as an adjunct therapy for the treatment of adult patients suffering from Obsessive-Compulsive Disorder (OCD).
